Immune protection againt Trypanosoma cruzi infection: Efficacy of two new generation adjuvants to formulate a subunit vaccine with Tran-Sialidase antigen

IVAN A BONTEMPI; GABRIEL CABRERA; MIGUEL H VICCO; DAIANA BERTONA; SILVINA RAQUEL VILLAR; FLORENCIA GONZALES; NAZARENA PUJATO; ALSIDES NICASTRO; ANA ROSA PEREZ; IVAN S MARCIPAR

Mar del Plata

Congreso; la Reunión Conjunta 2014 entre la Sociedad Argentina de Investigación Clínica (SAIC) y la Sociedad Argentina de Inmunología (SAI); 2014

Sociedad Argentina de Investigación Clínica (SAIC) y la Sociedad Argentina de Inmunología (SAI)

New generations adjuvants are able to enhance the efficacy of recombinant protein vaccines which are considered to be the safer ones but which typically promotes weak Immune responses. ISCOMATRIX (IMX) is a particularly special adjuvant as it has shown to be effective and safe in human clinical trials of vaccines designed to control intracellular infections by promoting a CTL response. Therefore, as a first step we assessed the immune protection achieved using this adjuvant to formulate mutant inactive trans-sialidase (mTS), previously proven to be highly protective against T. cruzi infection. Mice were immunized with mTS-IMX, mTS-IFA (IFA, incomplete Freund adjuvant), mTS (without adjuvant), IMX (without antigen) and PBS. mTS-IMX showed a TS-specific IgG response with titers >106 and high avidity, an increased IgG2a/IgG1 ratio, significant delayed-type hypersensitivity (DTH) reactivity and a balanced IFN- and IL-10 production, compared to mice immunized with mTS or IMX in PBS or vehicle (PBS) (p